Blog
RSS FeedPosted by Michael Wonder on 04 Jul 2018
PBAC to adopt a revised approach to considering brand equivalence/substitution for biosimilar medicines
4 July 2018 - PBAC to consult with Medicines Australia on the possible withdrawal of the TGA-PBAC parallel process for ...
Posted by Michael Wonder on 03 Jul 2018
PBAC rejects first submission supported by real-world evidence
4 July 2018 - A retrospective chart review of 211 Australian patients with chronic migraine served as the key evidentiary basis ...
Posted by Michael Wonder on 03 Jul 2018
NICE says Tookad too expensive for prostate cancer
3 July 2018 - The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 02 Jul 2018
Another multi-product proposal from Novartis, this time involving ten pharmaceuticals
2 July 2018 - PHARMAC is seeking feedback on a proposal to fund five new treatments, widen access to three ...
Posted by Michael Wonder on 02 Jul 2018
Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars ...
Posted by Michael Wonder on 01 Jul 2018
Private health insurance a hard sell to Medicare generation
30 June 2018 - The Coalition’s health insurance reforms are needed to prevent a decade-long decline in the sector, according ...
Posted by Michael Wonder on 01 Jul 2018
NICE rejects ocrelizumab (Ocrevus) for primary progressive MS in England and Wales
29 June 2018 - The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment ...
Posted by Michael Wonder on 01 Jul 2018
A drug that elongates life in breast cancer patients listed on PBS today - but only for some
1 July 2018 - They are two women from the same city who have exactly the same deadly disease. ...
Posted by Michael Wonder on 30 Jun 2018
New Zealand Pharmaceutical Schedule - 1 July 2018 update
1 July 2018 - The July 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Jun 2018
Price of breast cancer drug ribociclib cut after being placed on Pharmaceutical Benefits Scheme
30 June 2018 - The breast cancer drug ribociclib has been placed on the Pharmaceutical Benefits Scheme, taking the price from ...
Posted by Michael Wonder on 30 Jun 2018
Schedule of Pharmaceutical Benefits - 1 July 2018 update
1 July 2018 - The July 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jun 2018
PBS and NIP cost recovery - annual indexation of fees
1 July 2018 - The recovery of fees associated with the evaluation and listing of medicines, vaccines and other products ...
Posted by Michael Wonder on 28 Jun 2018
'Not at a crisis point yet': Doctors defend going private to give birth
29 June 2018 - A decline in the numbers of women giving birth through the private health system, and associated ...
Posted by Michael Wonder on 28 Jun 2018
High cost specialty drugs continue to dominate the new drug landscape
26 June 2018 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, ...